New research reveals that patients who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end traditional lifestyle programs.
Published data in a prominent medical journal demonstrates that while obese people can lose a large proportion of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month after stopping.
"People using such treatments need to be informed of the potential of quick rebound weight gain when the medication is stopped," cautioned researcher Dr. Susan Jebb.
That rate of regain means a reversion to starting mass within about a year and a half.
Weighing Treatments
The study, which looked at 37 of trials involving thousands of patients, compared the outcomes of these new drugs with older methods.
Scientists point out that individuals who lose weight through dieting usually have a slower creep back—around 0.1 kg a month—post-intervention.
The Reason for the Quick Regain
Nutrition scientists believe the mode of action of the injections is key to understanding the amplified regain.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of the hormone levels far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' leads to appetite is no longer kept in check, making binge eating much more probable."
A Lifelong Condition?
Health authorities suggest the jabs for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians contend that, due to the high risk of relapse, the therapy should be considered long-term.
This perspective is echoed by pharmaceutical companies, who say that the findings "underscore the chronic character of obesity," akin to managing diseases like diabetes.
Patient Testimonies
People who have discontinued the jabs report a sudden resurgence of appetite.
"It was like something activating and you become ravenous," said an individual.
The struggle is worsened if individuals have not established permanent dietary or behavioural changes during therapy.
Widespread Use
Survey data suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is higher among females compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Finally, researchers stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone cure and maintained weight loss hinges on integrated behavioural support.
